MedTrace Logo

Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant

NCT02597907 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2017-04-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to compare the antiemetic efficacy of aprepitant plus palonosetron versus aprepitant plus ramosetron in high risk patients undergoing laparoscopic cholecystectomy.

Conditions

  • Postoperative Nausea and Vomiting

Interventions

DRUG

aprepitant

aprepitant 80 mg is given to all patients before surgery

DRUG

palonosetron

palonosetron 0.075 mg is given to patients in the aprepitant plus palonosetron group after induction of general anesthesia

DRUG

Ramosetron

ramosetron 0.3 mg is given to patients in the aprepitant plus ramosetron group after induction of general anesthesia

Sponsors & Collaborators

  • Kyungpook National University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-05-31
Completion
2015-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02597907 on ClinicalTrials.gov